Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + trastuzumab + lapatinib vs paclitaxel + trastuzumab + placebo in HER2-positive metastatic breast cancer
2005-003432-22Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HER2-enriched breast cancer (HER2+) comparing Paclitaxel + trastuzumab + lapatinib with Paclitaxel + trastuzumab + placebo (2 arms). Primary endpoint: Time to Progression. Started Jan 2008; status: completed.
02
Drugs
lapatinib
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2005-003432-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003432-22.